About This Report

This databook provides a projection and analysis of IT spending in the pharma/biotech markets through to 2013 in Italy. The segments covered include big pharma, mid pharma, biotech, and small pharma/biotech.

What's In This Report

*The databook provides projections relating to total pharmaceutical IT spending in Italy through to 2013

*In each sub-sector, pharmaceutical IT spending is sector ed by hardware, software and services

*Contains pharmaceutical IT spending projections in Italy in relation to the wider region

Key Market Facts

The big pharma segment led the pharmaceutical IT spending in Italy accounting for 54.8% of the total IT spending in 2007.

Pharmaceutical IT spending in Italy is expected to increase at a growth rate (CAGR) of 4.2% over the 2008-13 period.

Italy accounted for 10.3% of the total pharmaceutical IT spending in Europe in 2007.

Why Should You Buy This Report?

*Understand the opportunity for technology spending in the life science industry

*Identify potential areas for spending growth amongst pharmaceutical and biotechnology firms

*Contains an analysis of pharmaceutical IT spending projection by each segment in Italy

Table Of Contents

TABLE OF CONTENTS
OVERVIEW 1
Catalyst 1
Summary 1
INTRODUCTION 5
Reasons to purchase 5
PHARMACEUTICAL IT SPENDING 6
Pharmaceutical IT spending projection in Italy to 2013 6
PHARMACEUTICAL IT SPENDING IN Euros OPE and Italy 9
Comparison of Pharmaceutical IT spending in Italy and EUR pe to 2013 9
Pharmaceutical IT spending in EUR pe by segment 2013 10
PHARMACEUTICAL IT SPENDING BY SECTOR 12
Big pharma segment projection 12
Mid pharma segment projection 14
Biotech segment projection 16
Small pharma/biotech projection 18
APPENDIX 20
Further reading 20
How to contact experts in your market 20
Disclaimer 20


Index of Figures
Chart 1: Pharmaceutical IT spending in Italy, 2007-2013 ($m) 6
Chart 2: Pharmaceutical IT spending in EUR pe and Italy, 2007-2013 ($m) 9
Chart 3: Pharmaceutical IT spending in EUR pe, 2007-2013 (%) 10
Chart 4: IT spending in the big pharma segment in Italy, 2007-2013 (%) 12
Chart 5: IT spending in the mid pharma segment in Italy, 2007-2013 (%) 14
Chart 6: IT spending in the biotech segment in Italy, 2007-2013 (%) 16
Chart 7: IT spending in the small pharma/biotech segment in Italy, 2007-2013 (%) 18


Index of Tables
Data table 1: Pharmaceutical IT spending data specifications: 5
Data table 2: Pharmaceutical IT spending in Italy, 2007-2013 ($m) 7
Data table 3: Pharmaceutical IT spending in Italy, 2007-2013 (%) 8
Data table 4: Pharmaceutical IT spending in EUR pe and Italy, 2007-2013 ($m) 9
Data table 5: Pharmaceutical IT spending in EUR pe, 2007-2013 ($m) 11
Data table 6: IT spending in the big pharma segment in Italy, 2007-2013 ($m) 13
Data table 7: IT spending in the mid pharma segment in Italy, 2007-2013 ($m) 15
Data table 8: IT spending in the biotech segment in Italy, 2007-2013 ($m) 17
Data table 9: IT spending in the small pharma/biotech segment in Italy, 2007-2013 ($m) 19


View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, ...

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected ...

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.